Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when JNJ files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsJ&J reports Q2 sales of $25.3B (+6.6%), raises 2026 guidance to $101.1B revenue and $11.68 EPS
Filed July 15, 2026 · Period ending July 15, 2026 · ~2 min read
Key Changes
-
high
Q2 2026 sales reached $25.3B (+6.6% YoY, +5.6% operational), with adjusted EPS of $2.90 (+4.7% YoY). Innovative Medicine grew 7.8% driven by oncology (DARZALEX +20.7%, CARVYKTI +31.7%) and TREMFYA (+84.2%), partially offset by STELARA's 68.8% U.S. decline from biosimilar competition.
Exhibit 99.1 view on EDGAR → -
high
Full-year 2026 guidance raised to $101.1B revenue (7.3% growth at midpoint, up from $100.8B prior) and adjusted EPS of $11.68 (8.2% growth, up $0.13). Adjusted operational EPS increased $0.18 to $11.58 (7.3% growth).
Exhibit 99.1 view on EDGAR → -
high
MedTech segment sales grew 4.5% to $8.9B, led by Cardiovascular (+8.3%, including Shockwave +14.6% and Electrophysiology +8.3%), Surgery (+4.3%), Vision (+6.3%), and Orthopaedics (+5.6%).
Exhibit 99.2 view on EDGAR → -
medium
FDA approved TREMFYA label expansion as the only IL-23 inhibitor proven to stop joint damage in psoriatic arthritis, and approved CAPLYTA for prevention of relapse in schizophrenia. J&J also announced acquisition of Firefly Bio to expand oncology pipeline with degrader antibody conjugate platform.
Exhibit 99.1 view on EDGAR → -
medium
Launched supply chain restructuring program in Innovative Medicine to exit certain manufacturing locations, with expected costs of $650-750M through fiscal 2029. Q2 2026 recorded $200M in restructuring charges, primarily asset impairments.
Exhibit 99.2 view on EDGAR →
Summary
Johnson & Johnson delivered strong second-quarter results and raised its full-year outlook, signaling confidence in its growth trajectory as it approaches $100 billion in annual revenue for the first time in its 140-year history. Q2 sales of $25.3 billion grew 6.6% year-over-year, with adjusted EPS of $2.90 up 4.7%.
The Innovative Medicine segment led growth at 7.8%, driven by oncology franchises DARZALEX and CARVYKTI, immunology product TREMFYA, and neuroscience assets SPRAVATO and CAPLYTA. STELARA's 68.8% U.S. decline from biosimilar competition created a 760-basis-point headwind to segment growth, as expected. MedTech grew 4.5%, with cardiovascular products (including the acquired Shockwave platform) posting 8.3% growth.
The company raised full-year 2026 guidance to $101.1 billion in revenue (up from $100.8 billion) and $11.68 adjusted EPS (up $0.13), reflecting operational strength across both segments. Recent FDA approvals for TREMFYA's joint-damage indication and CAPLYTA's relapse-prevention use expand addressable markets for key growth products. The Firefly Bio acquisition adds a novel degrader antibody conjugate platform to the oncology pipeline. J&J also launched a supply chain restructuring program to exit certain Innovative Medicine manufacturing sites, with $650-750 million in expected costs through 2029 and $200 million recorded in Q2. For holders, the guidance raise and product momentum support the growth narrative, though STELARA erosion will remain a near-term offset.
Section-by-Section Diff
Event · Exhibit 99.1
Added in current filing · view on EDGAR →
2026 Second-Quarter reported sales growth of 6.6% to $25.3 Billion with operational growth of 5.6%* and adjusted operational growth of 5.7%* •2026 Second-Quarter earnings per share (EPS) of $2.27 and adjusted EPS* of $2.90
Johnson & Johnson reported second-quarter 2026 sales of $25.3 billion, up 6.6% year-over-year, with operational growth of 5.6% and adjusted operational growth of 5.7%. Adjusted earnings per share reached $2.90, up 4.7% from $2.77 in Q2 2025, while reported EPS was $2.27. The company noted this marks quarterly sales surpassing $25 billion as it tracks toward exceeding $100 billion in annual revenue for the first time in its 140-year history.
Added in current filing · view on EDGAR →
Innovative Medicine worldwide operational sales grew 6.8%*, with divestitures negatively impacting growth by 10 basis points. Growth was primarily driven by DARZALEX, CARVYKTI, TECVAYLI and RYBREVANT/LAZCLUZE in Oncology, TREMFYA and Other Immunology in Immunology, and SPRAVATO and CAPLYTA in Neuroscience. Growth was partially offset by STELARA (an approximate 760 basis points impact) and REMICADE in Immunology, as well as IMBRUVICA and ZYTIGA in Oncology. MedTech MedTech worldwide operational sales grew 3.6%*, with net acquisitions and divestitures negatively impacting growth by 10 basis points. Growth was primarily driven by wound closure products and biosurgery products in Surgery, electrophysiology products and Shockwave in Cardiovascular, contact lenses in Vision, and trauma in Orthopaedics.
The Innovative Medicine segment grew operational sales 6.8%, driven by oncology products (DARZALEX, CARVYKTI, TECVAYLI, RYBREVANT/LAZCLUZE), immunology (TREMFYA), and neuroscience (SPRAVATO, CAPLYTA), though STELARA headwinds reduced growth by approximately 760 basis points. The MedTech segment grew operational sales 3.6%, led by surgery products (wound closure, biosurgery), cardiovascular (electrophysiology, Shockwave), vision (contact lenses), and orthopaedics (trauma). Both segments faced minor negative impacts from divestitures.
Added in current filing · view on EDGAR →
FDA approves label expansion, cementing TREMFYA as the only IL‑23 inhibitor proven to help stop further joint damage ... FDA approves CAPLYTA (lumateperone) sNDA with robust new data supporting reduced risk of relapse in schizophrenia
Johnson & Johnson received FDA approval for TREMFYA to inhibit the progression of structural joint damage in adults with active psoriatic arthritis, positioning it as the only IL-23 inhibitor with this indication. The FDA also approved CAPLYTA for the prevention of relapse in schizophrenia. Additionally, the company announced FDA approval for the Dual Energy THERMOCOOL SMARTTOUCH SF platform in cardiovascular procedures.
Added in current filing · view on EDGAR →
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
Johnson & Johnson announced an agreement to acquire Firefly Bio, Inc., which will expand the company's oncology pipeline with a novel degrader antibody conjugate platform. The acquisition represents a strategic investment in next-generation oncology therapeutics, though financial terms were not disclosed in this filing.
Event · Exhibit 99.2
Added in current filing · view on EDGAR →
Worldwide $25,310 23,743 6.6 % 5.6 1.0
Johnson & Johnson reported worldwide sales of $25,310 million for Q2 2026, up 6.6% from $23,743 million in Q2 2025. Operational growth (excluding currency effects) was 5.6%, with currency contributing 1.0 percentage point. U.S. sales grew 7.3% to $0.0M while international sales increased 5.7% to $0.0M.
Added in current filing · view on EDGAR →
Adjusted Net Earnings , after tax $7,081 $6,699 $13,695 $13,405 Average shares outstanding (Diluted) 2,440.1 2,419.1 2,443.9 2,423.3 Adjusted net earnings per share (Diluted) $2.90 $2.77 $5.60 $5.53
J&J reported adjusted diluted EPS of $2.90 for Q2 2026, up 4.7% from $2.77 in Q2 2025. Adjusted net earnings were $7,081 million versus $6,699 million prior year. The adjusted figures exclude intangible amortization ($1,245M), litigation ($267M), restructuring ($276M), orthopaedics separation costs ($258M), and other items totaling approximately $1.5 billion pre-tax.
Added in current filing · view on EDGAR →
Innovative Medicine | U.S. $ 9,979 9,161 8.9 % 8.9 — | International 6,405 6,041 6.0 3.6 2.4 | 16,384 15,202 7.8 6.8 1.0
The Innovative Medicine segment posted Q2 2026 sales of $16,384 million, up 7.8% (6.8% operational). U.S. sales grew 8.9% to $9,979 million, driven by oncology products (DARZALEX up 20.7%, CARVYKTI up 31.7%) and TREMFYA in immunology (up 84.2%). International sales rose 6.0% to $0.0M. STELARA declined 68.8% in the U.S. due to biosimilar competition.
Added in current filing · view on EDGAR →
MedTech | U.S. 4,554 4,383 3.9 3.9 — | International 4,372 4,158 5.2 3.2 2.0 | 8,926 8,541 4.5 3.6 0.9
The MedTech segment reported Q2 2026 sales of $8,926 million, up 4.5% (3.6% operational). U.S. sales increased 3.9% to $4,554 million while international sales grew 5.2% to $4,372 million. Cardiovascular led growth at 8.3% worldwide, driven by Electrophysiology (+8.3%) and Shockwave (+14.6%). Surgery grew 4.3%, Vision 6.3%, and Orthopaedics 5.6%.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 16, 2026 · How we verify